5 ways to optimize CT lung cancer screening

An academic hospital that implemented a CT lung cancer screening program obtained...Read more on AuntMinnie.comRelated Reading: Stricter CT lung screening criteria deal mixed results Cancer deaths continue to fall, but CT lung screening lags Risk-based lung cancer screening tops USPSTF guidelines Chest doctors issue guidelines for CT lung cancer screening Canadian risk model boosts CT lung screening efficiency
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

During the production of this paper, an error appeared in the title. The title should be, “Immune Checkpoint Inhibition Combined With Intracranial Stereotactic Radiation Therapy in Non-Small Cell Lung Cancer: Is There an Increasing Rate of Radionecrosis or Not? In Regards to Schapira et al, Huppeling et al and Colaco et al.”
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Tags: Erratum Source Type: research
MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1. Mol Med Rep. 2018 Nov 29;: Authors: Zhu J, Tao L, Jin L Abstract Epidermal growth factor receptor‑tyrosine kinase inhibitors, such as gefitinib, have been found to be clinically effective in the treatment of patients with non‑small cell lung cancer (NSCLC). However, the therapeutic effect of gefitinib is often limited by the development of gefitinib resistance. MicroRNAs (miRNAs), a group of small non‑coding RNAs, have been demonstrated to be frequently dysregulated in human ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L. Mol Med Rep. 2018 Dec 04;: Authors: Chen X, Zhu H, Ye W, Cui Y, Chen M Abstract Cisplatin‑based chemotherapy may greatly enhance patient prognosis; however, chemotherapy resistance remains an obstacle to curing patients with non‑small cell lung cancer (NSCLC). The aim of the present study was to explore the microRNAs (miRs) that could regulate cisplatin sensitivity and provide a potential treatment method for cisplatin resistance in clinical. Results from the present study revealed that mi...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Publication date: Available online 11 December 2018Source: Pathology - Research and PracticeAuthor(s): You Zhou, Xiao Zheng, Lu-jun Chen, Bin Xu, Jing-ting JiangAbstractBackgroundThe aim of the study was to measure the expression of microRNA (miR)-181b in patients with lung cancer, investigate its biological function and elucidate the underlying mechanisms associated with the development of lung cancer.MethodsmiR-181b expression in tissues was measured via RT-qPCR. After A549 cells were transfected with miR-181b mimic or si-Sox6, the proliferation, migration and cell cycle distribution of A549 were evaluated using cell cou...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
In this study, the expression level of FBXL3 in NSCLC tissues and cell lines was firstly examined and identified. Moreover, the relationship between FBXL3 and the overall survival rate of NSCLC patients was analyzed by Kaplan–Meier survival curve. Functionally, MTT, colony formation assay and transwell assays were performed to determine the role of FBXL3 in regulating NSCLC cell proliferation, migration and invasion. The proliferation and migration were suppressed by overexpression of FBXL3, indicating the potential tumor suppressive role of FBXL3 in NSCLC. In addition, the dual-luciferase reporter and RNA pull-down ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
This case underscores the potential of the tyrosine kinase inhibitor alectinib to cause severe grade 4 renal toxicity, which was reversible in this patient with metastatic lung cancer.Journal of Medical Case Reports
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
ka Iyer Neuroendocrine tumors (NETs) are a group of malignancies that originated from neuroendocrine cells, with the most common sites being lungs and the gastrointestinal tract. Lung NETs comprise 25% of all lung malignancies. Small cell lung cancer is the most common form of lung NETs, and other rare forms include well-differentiated typical carcinoids (TCs) and poorly differentiated atypical carcinoids (ACs). Given the paucity of randomized studies, rational treatment is challenging. Therefore, it is recommended that these decisions be made using a multidisciplinary collaborative approach. Surgery remains the mainst...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study investigated correlations of the clinical outcomes of oral metronomic vinorelbine (VNR) with VNR pharmacokinetics and MDR1 polymorphisms.MethodsEighty-two patients with metastatic non-small cell lung cancer (NSCLC) unfit for standard chemotherapy were treated with VNR at the oral doses of 20 –30 mg every other day or 50 mg three times a week. They had a performance status (PS) ≤ 3, were>  70-year-old and drug-naïve or cisplatin-pretreated. MDR1 2677G >  T and 3435C >  T polymorphisms were analysed and blood concentrations of VNR an...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionEGFR T790M mutation is a major mechanism of acquired resistance to afatinib. Osimertinib confers high response rates after afatinib failure inEGFR T790M-positive patients and its use in sequence potentially allows extended chemotherapy-free treatment.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
The long-term results from an analysis of two phase II studies confirmed the role of osimertinib in the treatment of T790M mutation –positive advanced non–small-cell lung cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Academia | Canada Health | Cancer | Cancer & Oncology | Hospitals | Lung Cancer